NAA20 Antibody

What is NAA20 and what cellular functions does it regulate?

NAA20 serves as the catalytic subunit of the N-terminal acetyltransferase B (NatB) complex, which is responsible for approximately 20% of the proteome's N-terminal acetylation . This post-translational modification is among the most prevalent in eukaryotic proteins. NAA20 has been implicated in hepatocellular carcinoma (HCC) progression through its ability to inhibit the AMP-activated protein kinase (AMPK) pathway, thereby promoting the mammalian target of rapamycin signaling pathway . Additionally, NAA20 plays roles in cell proliferation, autophagy regulation, and tumorigenesis through its N-terminal acetyltransferase (NAT) activity . In yeast models, NAA20 deficiency leads to slow growth phenotypes, defects in actin cable formation, compromised vacuolar and mitochondrial inheritance, and increased sensitivity to DNA-damaging agents .

What research applications are NAA20 antibodies suitable for?

NAA20 antibodies have been validated for multiple research applications including:

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of NAA20 in solution (recommended dilution: 1 μg/ml)

• Western Blotting (WB): For identifying NAA20 protein in cell or tissue lysates (recommended dilution range: 1/500 - 1/2000)

• Immunohistochemistry on paraffin sections (IHC-P): For visualizing NAA20 distribution in tissue samples (recommended dilution range: 1/50 - 1/200)

• Immunoprecipitation (IP): For isolating NAA20 protein complexes from cell extracts (recommended amount: 0.5-4 μg antibody per 200-400 μg of whole cell extracts)

What are the optimal storage conditions for maintaining NAA20 antibody activity?

For optimal preservation of antibody function, NAA20 antibodies should be aliquoted upon receipt and stored at -20°C . Repeated freeze-thaw cycles should be strictly avoided as they can lead to denaturation and loss of antibody functionality . The antibody is typically supplied in PBS (pH 7.3) containing 0.09% sodium azide and 50% glycerol, which helps maintain stability during storage . When handling the antibody for experiments, work on ice and return unused portions to -20°C immediately to preserve activity.

How should I validate the specificity of NAA20 antibodies for my experimental system?

To ensure antibody specificity for NAA20:

• Comparative analysis with genetic controls: Compare antibody reactivity in wild-type cells versus NAA20 knockdown or knockout samples to confirm signal specificity

• Peptide competition assay: Pre-incubate the antibody with the immunogenic peptide (amino acids 49-178 of human NAA20) before application to samples

• Cross-reactivity assessment: Test the antibody on samples from different species; the commercially available antibody shows reactivity with human, mouse, and rat NAA20

• Molecular weight verification: Confirm that the detected protein corresponds to the calculated molecular weight of NAA20 (20 kDa)

• Multiple detection methods: Validate findings using at least two different detection techniques (e.g., Western blot and immunohistochemistry)

What controls are essential when investigating NAA20's role in the LKB1-AMPK pathway?

When studying NAA20's effects on the LKB1-AMPK signaling axis:

• Positive controls: Include samples with known LKB1 and AMPK activation states (e.g., AICAR-treated cells for AMPK activation)

• Negative controls: Use NAA20 knockout/knockdown cells to demonstrate pathway regulation in the absence of NAA20

• Phosphorylation-specific controls: Monitor phosphorylation levels of LKB1 (S428) and AMPK as pathway activation indicators

• Mutant LKB1 controls: Compare effects with non-acetylatable LKB1-MPE mutant to validate acetylation-dependent effects

• Experimental intervention controls: Include mTOR inhibitors (e.g., rapamycin) to assess downstream effects of NAA20-mediated AMPK inhibition

How can I optimize NAA20 antibody concentrations for different experimental applications?

How can NAA20 antibodies be used to investigate NAA20's role in tumor progression?

For investigating NAA20's oncogenic properties in cancer research:

• Expression profiling: Use IHC and Western blot to compare NAA20 expression between tumor and adjacent normal tissues, correlating with clinical parameters

• Co-immunoprecipitation studies: Employ NAA20 antibodies to isolate and identify interaction partners in the oncogenic pathway, particularly components of the LKB1-AMPK-mTOR axis

• ChIP sequencing approaches: Combine NAA20 antibodies with chromatin immunoprecipitation to identify potential DNA-binding sites if nuclear localization is observed

• Phosphorylation cascade analysis: Use NAA20 antibodies alongside phospho-specific antibodies for LKB1 (S428) and AMPK to map signaling cascades in tumor models

• Therapeutic intervention assessment: Evaluate NAA20 expression changes following treatment with potential therapeutic agents targeting the mTOR pathway

What methodological approaches can distinguish between free NAA20 and NAA20 in the NatB complex?

To differentiate between uncomplexed NAA20 and NAA20 within the NatB complex:

• Sequential immunoprecipitation: First immunoprecipitate with Naa25 antibodies, then analyze the unbound fraction for free NAA20

• Size exclusion chromatography: Separate protein complexes by size followed by Western blot detection of NAA20

• Gradient ultracentrifugation: Isolate protein complexes of different molecular weights and analyze fractions for NAA20

• Enzyme activity assays: Compare acetylation activity between purified recombinant NAA20 and the complete NatB complex using peptide substrates (e.g., MDEL peptide)

• Kinetic parameter analysis: Measure substrate affinity differences between free NAA20 (Km for MDEL peptide ~4.4 mM) versus NAA20 in NatB complex (Km ~232 μM)

How can NAA20 antibodies help investigate N-terminal acetylation mechanisms?

For mechanistic studies of N-terminal acetylation:

• Substrate identification: Use NAA20 antibodies in immunoprecipitation followed by mass spectrometry to identify novel substrate proteins

• Structural analysis support: Combine with crystallographic data to validate structural predictions about NAA20's substrate binding pocket

• Enzymatic mechanism studies: Use site-directed mutagenesis to modify key residues identified in the crystal structure (e.g., the substrate binding pocket that accommodates the MDEL peptide) , then analyze with NAA20 antibodies

• Inhibitor development assessment: Evaluate binding of potential competitive inhibitors such as CoA-Ac-MDEL (IC50 ~6.5 μM for NAA20 alone)

• Ribosomal association studies: Investigate whether NAA20 requires Naa25 for ribosomal association using subcellular fractionation and immunodetection

How should researchers interpret discrepancies between NAA20 activity and expression levels?

When facing discrepancies between NAA20 protein levels and activity measurements:

• Post-translational modification analysis: Investigate whether NAA20 itself undergoes modifications that affect its activity using phospho-specific or ubiquitin-specific antibodies alongside NAA20 antibodies

• Complex formation assessment: Evaluate Naa25 levels, as it significantly enhances NAA20's substrate affinity (reducing Km from 4.4 mM to 232 μM)

• Substrate availability: Measure levels of key substrates like LKB1, as substrate limitation could explain activity variations despite consistent expression

• Inhibitory factors: Consider the presence of endogenous inhibitors that may compete with NAA20 substrates

• Enzymatic activity assays: Perform direct NAT activity measurements using recombinant substrates and compare with expression levels detected by antibodies

What approaches can resolve non-specific signals when using NAA20 antibodies?

To address non-specific binding issues:

• Optimization of blocking conditions: Test different blocking agents (BSA, non-fat milk, commercial blockers) at various concentrations and durations

• Antibody titration: Perform careful dilution series to identify the optimal concentration that maximizes specific signal while minimizing background

• Cross-adsorption: Pre-adsorb the antibody with tissue/cell lysates from species not being tested

• Alternative detection systems: Compare different secondary antibodies and detection methods (HRP vs. fluorescence)

• Sample preparation refinement: Optimize lysis conditions, particularly detergent types and concentrations, to improve specificity

How can researchers effectively study NAA20's impact on the LKB1-AMPK pathway?

For robust analysis of NAA20's effects on LKB1-AMPK signaling:

• Phosphorylation status monitoring: Track phosphorylation of LKB1 at S428 and corresponding AMPK activation in response to NAA20 manipulation

• Non-acetylatable mutant comparisons: Utilize LKB1-MPE mutant (non-acetylatable form) to confirm effects are acetylation-dependent

• Rescue experiments: Conduct complementation studies in NAA20-deficient cells with wild-type versus catalytically inactive NAA20 mutants

• Pathway component knockdown: Perform sequential knockdown of pathway components (LKB1, AMPK) to dissect epistatic relationships with NAA20

• Substrate identification verification: Confirm NAA20's direct acetylation of LKB1 using in vitro acetylation assays with recombinant proteins and mass spectrometry analysis

What emerging applications of NAA20 antibodies might advance cancer research?

Promising research directions for NAA20 antibodies in cancer investigation include:

• Biomarker development: Evaluate NAA20 as a prognostic or predictive biomarker in hepatocellular carcinoma and other cancer types

• Therapeutic target validation: Use antibodies to confirm target engagement in drug development efforts aimed at inhibiting NAA20

• Resistance mechanism investigation: Study NAA20 expression and activity in treatment-resistant cancer models

• Cancer metabolism connections: Explore links between NAA20-mediated AMPK inhibition and metabolic reprogramming in tumors

• Combinatorial therapy assessment: Investigate NAA20 expression changes in response to standard treatments to identify potential synergistic therapeutic approaches

How might structural insights from crystallography inform NAA20 antibody applications?

The crystal structure of NAA20 in complex with CoA-Ac-MDEL at 1.57 Å resolution provides opportunities for:

• Epitope-specific antibody development: Design antibodies against functionally critical regions identified in the structure

• Conformational state-specific antibodies: Develop antibodies that recognize NAA20 in different substrate-bound states

• Structure-guided inhibitor screening: Use structural insights to develop specific NAT inhibitors for drug development

• Mutational analysis tools: Create antibodies against common NAA20 mutations to study structure-function relationships

• Allosteric regulation investigation: Identify potential allosteric binding sites from the crystal structure that might be targeted for regulation